AMCo (Formerly Amdipharm Mercury Ltd)

AMCo, formerly known as Amdipharm Mercury Ltd, is a rapidly-growing international pharmaceutical company operating in the biotechnology, healthcare, manufacturing, and pharmaceutical industries. With a focus on supplying niche medicines to over 100 countries worldwide, the company aims to make a real difference to patients, doctors, hospitals, and healthcare authorities. Founded in 2003, AMCo has been actively building its portfolio of global niche medicines through strategic acquisitions, in-licensing, and internal developments. The result of a 2013 merger between Amdipharm and the Mercury Pharma Group, AMCo has since expanded through the acquisition of other pharmaceutical companies and medicines. This growth includes the recent acquisitions of the UK-based Focus Group and Sweden-based Abcur AB, as well as the product acquisition of Fucithalmic® from LEO Pharma in 2013. With a well-established international distribution network and a proven track record in sales and marketing of prescription medicines, AMCo operates with small, focused teams possessing local knowledge and supporting effective local healthcare solutions. This has led to an increase in sales in the 112 countries in which the company operates. AMCo's involvement in the highly effective generics industry in the UK, estimated to save the UK’s NHS almost £9 billion pounds in healthcare costs each year (source: British Generic Manufacturers Association), underscores its commitment to offering wide-ranging portfolio of niche prescription-only medicines, with opportunities for expansion in the future. As an international player with a strong foothold in the global pharmaceutical market, AMCo presents an attractive opportunity for potential investors seeking to tap into the rapidly-evolving landscape of niche medicines and the broader healthcare sector.